6:34 PM
 | 
Oct 31, 2012
 |  BC Extra  |  Company News

EC conditionally approves Seattle Genetics' Adcetris

Seattle Genetics Inc. (NASDAQ:SGEN) and partner Millennium Pharmaceuticals Inc. said the European Commission conditionally approved an MAA for Adcetris brentuximab vedotin to treat anaplastic large cell lymphoma (ALCL) and Hodgkin's lymphoma. Specifically, Adcetris is approved for relapsed or refractory systemic...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >